{
  "ticker": "LLY",
  "target_date": "2025-06-30",
  "actual_date": "2025-06-30",
  "collected_at": "2025-12-08T11:57:15.438981",
  "price": {
    "open": 775.69,
    "high": 782.13,
    "low": 771.17,
    "close": 776.6809692382812,
    "volume": 3041500,
    "change_1d_pct": 0.53,
    "change_7d_pct": -0.7,
    "change_30d_pct": 6.52
  },
  "technicals": {
    "rsi_14": 51.84,
    "sma_20": 780.03,
    "sma_50": 778.97,
    "macd": 4.512,
    "macd_signal": 5.402,
    "macd_histogram": -0.889,
    "bb_upper": 821.31,
    "bb_lower": 738.76,
    "price_vs_sma20_pct": -0.43,
    "price_vs_sma50_pct": -0.29,
    "volume_ratio": 0.94
  },
  "fundamentals": {
    "market_cap": 892808200192,
    "pe_ratio": 48.796177,
    "forward_pe": 43.951015,
    "price_to_book": 37.497364,
    "price_to_sales": 15.025433,
    "profit_margin": 30.99,
    "operating_margin": 48.29,
    "roe": 96.47,
    "roa": 17.6,
    "revenue_growth": 53.9,
    "earnings_growth": 480.4,
    "debt_to_equity": 178.516,
    "current_ratio": 1.546,
    "quick_ratio": 0.724,
    "dividend_yield": 59.0,
    "fifty_two_week_high": 1111.99,
    "fifty_two_week_low": 623.78,
    "fifty_day_avg": 911.5326,
    "two_hundred_day_avg": 811.9354,
    "analyst_target": 1056.7045,
    "analyst_recommendation": "buy",
    "num_analysts": 27,
    "sector": "Healthcare",
    "industry": "Drug Manufacturers - General",
    "pct_from_52w_high": -10.44,
    "pct_from_52w_low": 59.66
  },
  "macro": {
    "spy": {
      "price": 616.14,
      "change_1d_pct": 0.48,
      "change_7d_pct": 3.97
    },
    "vix": {
      "level": 16.73,
      "signal": "NORMAL"
    },
    "treasury_10y": {
      "yield_pct": 4.23
    },
    "dollar_index": {
      "level": 96.88
    },
    "gold": {
      "price": 3294.4
    },
    "regime": "BULL_LOW_VOL"
  },
  "news": [
    {
      "headline": "FDA Approves Updated Label For Eli Lilly and Company (LLY)\u2019s Amyvid To Support Alzheimer\u2019s Diagnosis",
      "source": "Yahoo",
      "datetime": 1751317718,
      "summary": "Eli Lilly and Company (NYSE:LLY) is among the Goldman Sachs Stock Portfolio: 10 Large-Cap Stocks To Buy. On June 25, the company announced that the FDA had approved a label update for Amyvid to support the diagnosis of Alzheimer\u2019s disease. The florbetapir F 18 injection is used for brain imaging of ",
      "url": "https://finnhub.io/api/news?id=3455926d13ff1b58cc8af96cc8cd4a88d9b60322a56e537f570e62ec340db169"
    },
    {
      "headline": "Can Protagonist Take On Eli Lilly's Next-Generation Obesity Treatment?",
      "source": "Yahoo",
      "datetime": 1751313901,
      "summary": "Protagonist Therapeutics is taking aim directly at Eli Lilly's obesity treatment with a newly announced drug that uses the same mechanism.",
      "url": "https://finnhub.io/api/news?id=a41fbce3a267d3584c748a0066f35e342597111b0424027dbc0697f9b825d867"
    },
    {
      "headline": "Eli Lilly (LLY) Faces Bearish Options Flow, But Probabilities Tell a Different Story",
      "source": "Yahoo",
      "datetime": 1751304602,
      "summary": "Options traders leaned bearish on LLY stock, but market demand data reveals conditional odds that may support near-term upside.",
      "url": "https://finnhub.io/api/news?id=8a3beb4ed668a0b57ecdfc37a3dae4bd144a841bf78634eac431f87ff784cf5f"
    },
    {
      "headline": "Will CVS Health's Formulary Move Boost Its Weight Management Program? (Revised)",
      "source": "Yahoo",
      "datetime": 1751293620,
      "summary": "CVS adds Wegovy to its top formularies and bolsters its Weight Management program, aiming to expand access while cutting costs.",
      "url": "https://finnhub.io/api/news?id=1195d1c5183c46b4bfb2e8137f877465cceb36252b0fb31eef30b4fc80a7fc91"
    },
    {
      "headline": "RBC says Lilly could blaze trail and Biogen could pull ahead in Alzheimer\u2019s market",
      "source": "Yahoo",
      "datetime": 1751285932,
      "summary": "Investing.com -- RBC Capital Markets analysts believe Eli Lilly\u2019s upcoming TRAILBLAZER-3 trial data on Kisunla could unlock a vast, largely untapped segment of the Alzheimer\u2019s treatment market and pave the way for Biogen\u2019s Leqembi to follow with significant commercial success.",
      "url": "https://finnhub.io/api/news?id=aa3fd58b3af4e34e4d99f93669cc36a6924b778285e9f813fadfcf28a283837d"
    }
  ],
  "news_count": 5,
  "sec_filings": [
    {
      "form": "4",
      "date": "2025-06-17",
      "description": "xslF345X05/wk-form4_1750199300.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/59478/000005947825000176/xslF345X05/wk-form4_1750199300.xml"
    },
    {
      "form": "4",
      "date": "2025-06-17",
      "description": "xslF345X05/wk-form4_1750199159.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/59478/000005947825000174/xslF345X05/wk-form4_1750199159.xml"
    },
    {
      "form": "4",
      "date": "2025-06-17",
      "description": "xslF345X05/wk-form4_1750198988.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/59478/000005947825000172/xslF345X05/wk-form4_1750198988.xml"
    },
    {
      "form": "4",
      "date": "2025-06-17",
      "description": "xslF345X05/wk-form4_1750198711.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/59478/000005947825000170/xslF345X05/wk-form4_1750198711.xml"
    },
    {
      "form": "4",
      "date": "2025-06-17",
      "description": "xslF345X05/wk-form4_1750198504.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/59478/000005947825000168/xslF345X05/wk-form4_1750198504.xml"
    }
  ],
  "sec_filings_count": 5,
  "data_quality": {
    "has_price": true,
    "has_technicals": true,
    "has_fundamentals": true,
    "has_macro": true,
    "has_news": true,
    "has_sec_filings": true
  }
}